We are monitoring the impact of COVID-19 on MEA Autoimmune Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1110
Share on
Share on

Middle East & Africa Autoimmune Monoclonal Antibodies Market Research Report – Segmented By Source, Application, End User & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends, Growth & Forecasts (2020 to 2025)

Pulished: February, 2020
ID: 1110
Pages: 145

MEA Autoimmune Monoclonal Antibodies Market Size & Growth (2020 to 2025)

The size of the Autoimmune Monoclonal Antibodies Market in the Middle East and Africa is expected to reach USD 1538.85 million by 2025 from USD 1108.4 million in 2020, growing at a CAGR of 6.78% during the forecast period 2020 to 2025. 

Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat a wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells not impacting the normal ones.

The increasing involvement of public & private organizations to support advanced therapeutics development, rising healthcare expenditure, and the growing number of the population are driving the growth of the autoimmune monoclonal antibodies market in Middle-East & Africa. However, lack of awareness among patients about advanced therapies, underdeveloped healthcare infrastructure, and high cost of monoclonal antibodies therapeutics are restraining the growth of autoimmune monoclonal antibodies market in Middle-East & Africa.

This research report on the MEA Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories

By Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

By Application:

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Transplant Rejection/Graft Versus Host Disease

By End-User: 

  • Hospitals/Clinics
  • Research Institutes
  • Diagnostic Laboratories

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Companies like GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium) are playing a leading role in the MEA Autoimmune Monoclonal Antibodies Market.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Source                    

                                5.1.1 Murine     

                                5.1.2 Chimeric  

                                5.1.3 Humanized             

                                5.1.4 Human     

                5.2 By Application                           

                                5.2.1 Systemic Lupus Erythematosus      

                                5.2.2 Rheumatoid Arthritis          

                                5.2.3 Multiple Sclerosis 

                                5.2.4 Transplant Rejection/Graft Versus Host Disease     

                                5.2.5 Others      

                5.3 End User                     

                                5.3.1 Hospitals/Clinics   

                                5.3.2 Research Institute

                                5.3.3 Diagnostic Laboratories     

6. Geographical Analysis                                              

                6.1 Middle East & Africa               

                                6.1.1 Introduction           

                                6.1.2 Middle-East            

                                6.1.3 Africa        

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

                7.5 Key Trends in Monoclonal Antibodies Development                 

                                7.5.1 Targeted Therapies             

                7.6 Promising Monoclonal Antibodies in Pipeline                              

                7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies                   

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 GlaxoSmithKline plc (U.K.)                   

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 AstraZeneca plc (U.K.)                           

                9.3 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.4 Bristol-Myers Squibb (U.S.)                 

                9.5 Johnson & Johnson (U.S.)                    

                9.6 Innovent Biologics, Inc. (China)                          

                9.7 Takeda Pharmaceutical Company Ltd. (Japan)                             

                9.8 Amgen Inc. (U.S.)                     

                9.6 Innovent Biologics, Inc. (China)                          

                9.10 UCB Company (Belgium)                    

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures     

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                  

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Autoimmune Monoclonal Antibodies Market By Region, From 2020 to 2025 ( USD Million )
  2. Middle East & Africa Autoimmune Monoclonal Antibodies Market By Source, From 2020 to 2025 ( USD Million )
  3. Middle East & Africa Murine Monoclonal Antibodies Market By Region, From 2020 to 2025 ( USD Million )
  4. Middle East & Africa Chimeric Monoclonal Antibodies Market By Region, From 2020 to 2025 ( USD Million )
  5. Middle East & Africa Humanized Monoclonal Antibodies Market By Region, From 2020 to 2025 ( USD Million )
  6. Middle East & Africa Human Monoclonal Antibodies Market By Region, From 2020 to 2025 ( USD Million )
  7. Middle East & Africa Autoimmune Monoclonal Antibodies Market By Application, From 2020 to 2025 ( USD Million )
  8. Middle East & Africa Systemic Lupus Erythematosus Market By Region, From 2020 to 2025 ( USD Million )
  9. Middle East & Africa Rheumatoid Arthritis Market By Region, From 2020 to 2025 ( USD Million )
  10. Middle East & Africa Multiple Sclerosis Market By Region, From 2020 to 2025 ( USD Million )
  11. Middle East & Africa Transplant Rejection/Graft Versus Host Disease Market By Region, From 2020 to 2025 ( USD Million )
  12. Middle East & Africa Other Applications Market By Region, From 2020 to 2025 ( USD Million )
  13. Middle East & Africa Autoimmune Monoclonal Antibodies Market By End User, From 2020 to 2025 ( USD Million )
  14. Middle East & Africa Hospitals/Clinics Market By Region, From 2020 to 2025 ( USD Million )
  15. Middle East & Africa Research Institute Market By Region, From 2020 to 2025 ( USD Million )
  16. Middle East & Africa Diagnostic Laboratories Market By Region, From 2020 to 2025 ( USD Million )
  17. Middle-East Autoimmune Monoclonal Antibodies Market By Source, From 2020 to 2025 ( USD Million )
  18. Middle-East Autoimmune Monoclonal Antibodies Market By Application, From 2020 to 2025 ( USD Million )
  19. Middle-East Autoimmune Monoclonal Antibodies Market By End User, From 2020 to 2025 ( USD Million )
  20. Africa Autoimmune Monoclonal Antibodies Market By Source, From 2020 to 2025 ( USD Million )
  21. Africa Autoimmune Monoclonal Antibodies Market By Application, From 2020 to 2025 ( USD Million )
  22. Africa Autoimmune Monoclonal Antibodies Market By End User, From 2020 to 2025 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample